Coherus Oncology
Coherus Oncology's revenue rose 59.8% to $42 million in fiscal 2025. Its operating margin was −429.5%, up from −756.6% a year earlier. The diluted share count rose 2.3%.
Operating margin is operating income as a share of revenue. Free cash flow is cash from operations minus capital spending. Return on equity is net income as a share of shareholders' equity. Market cap is the last closing share price times the latest diluted share count, so it is approximate. P/E is the last close divided by diluted earnings per share over the last four quarters, or the latest fiscal year where the quarters aren't available; there is none when the company made a loss.
Charts show fiscal years, from the 10-K filings.
What Coherus Oncology does
Coherus Oncology develops and sells cancer medicines that work with the immune system. Its one marketed product is LOQTORZI (toripalimab-tpzi), a PD-1 inhibitor, a drug that helps the immune system attack cancer cells. The FDA approved it in October 2023 for nasopharyngeal carcinoma, a cancer of the upper throat, and Coherus launched it in the United States in January 2024.
Coherus developed LOQTORZI with Junshi Biosciences. It earns money from sales of LOQTORZI. It plans to grow sales, add new uses for LOQTORZI and test it in combination with its own pipeline drugs: two mid-stage candidates, tagmokitug and casdozokitug, aimed at liver, head and neck, colorectal and other cancers.
It was called Coherus BioSciences until May 2025, when it changed its name after selling its biosimilar businesses and focusing on new immuno-oncology medicines.
Its biggest risks, as it describes them
- A limited history of profitability, with only one approved and marketed product.
- Needing to raise more funds, which may not be available on acceptable terms.
- Uncertain insurance coverage and reimbursement for its product.
- Competition from other immuno-oncology drugs, including those that may reach the market first.
- Heavy regulatory scrutiny of its product and candidates, even after approval.
Income statement
From fiscal 2019 to 2025, earnings per share grew 2.5% a year and net income 11.0% a year, as new shares raised the share count by 60% and diluted each share's earnings.
Returns on capital
Balance sheet
Five years at a glance
| Fiscal year end | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Cash and short-term investments | 417 | 192 | 118 | — | 172 |
| Debt incl. finance leases | 83 | — | — | — | — |
| Net debt (negative means net cash) | −335 | — | — | — | — |
| Net debt to EBITDA | — | — | — | — | — |
| Debt to equity | 0.8x | — | — | — | — |
| Interest coverage | −11.5x | −7.9x | −5.0x | −18.6x | −20.1x |
| Current ratio | 3.6x | 2.8x | 1.4x | 1.2x | 1.5x |
| Quick ratio | 3.4x | 2.5x | 1.2x | 1.2x | 1.4x |
Cash flow
Projections
Project Coherus Oncology's revenue, net income and earnings per share five years ahead in a bull, a base and a bear case with your own figures, and see the share prices your P/E estimates give them, or value it with a discounted cash flow model. Every projected figure is yours: it is not a forecast of ours.
Insider trades
No officer, director or 10% owner of Coherus Oncology reported buying or selling its shares on the open market between November 20, 2025 and November 19, 2026.
Indicators
Four widely used measures, worked out from the company's filings. The cutoffs are the ones their authors or users go by, not a verdict of ours.
| Indicator | FY23 | FY24 | FY25 |
|---|---|---|---|
| Piotroski F-score | — | — | — |
| Rule of 40 | −46.2% | — | — |
| Altman Z'' | −9.10 | −13.65 | −20.15 |
| Accruals ratio | −11.3% | 9.1% | 86.7% |
The nine F-score tests
| Test | FY23 | FY24 | FY25 |
|---|---|---|---|
| Net income is positive | Fail | Pass | Pass |
| Cash from operations is positive | Fail | Fail | Fail |
| Return on assets rose | Fail | Pass | Pass |
| Cash from operations exceeds net income | Pass | Fail | Fail |
| Debt fell relative to assets | — | — | — |
| Current ratio rose | Fail | Fail | Pass |
| Share count didn't rise | Fail | Fail | Fail |
| Gross margin rose | Fail | Pass | Pass |
| Revenue rose relative to assets | Pass | Fail | Pass |
| F-score | — | — | — |
Compare
Put Coherus Oncology side by side with any other company we cover: revenue, growth, margins, cash flow and returns, with ten years of charts.
Similar companies
| Company | Year | Revenue growth | Operating margin | Free cash flow margin | Return on capital | Net debt to EBITDA | F-score | Compare |
|---|---|---|---|---|---|---|---|---|
| Coherus Oncology | FY25 | 59.8% | −429.5% | — | — | — | — | |
| Wave Life Sciences | FY25 | −60.5% | −504.1% | −440.5% | — | — | — | Compare |
| Editas Medicine | FY25 | 25.4% | −394.9% | −409.3% | — | — | 2 | Compare |
| Voyager Therapeutics | FY25 | −49.5% | −326.6% | −334.5% | — | — | — | Compare |
| Fennec Pharmaceuticals | FY25 | −6.1% | −14.1% | — | — | — | — | Compare |
10 years of figures
| Fiscal year | FY16 | FY17 | FY18 | FY19 | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||||
| Revenue | 190 | 2 | 0 | 356 | 476 | 327 | 211 | 257 | 26 | 42 |
| Revenue growth | 532.8% | −99.2% | −100.0% | — | 33.6% | −31.4% | −35.4% | 21.9% | −89.7% | 59.8% |
| Gross profit | — | — | — | 339 | 438 | 269 | 141 | 98 | 18 | 28 |
| Research and development | 254 | 162 | 110 | 94 | 143 | 363 | 199 | 109 | 92 | 109 |
| Operating income | −116 | −232 | −204 | 108 | 156 | −264 | −257 | −203 | −200 | −181 |
| Net income | −127 | −238 | −209 | 90 | 132 | −287 | −292 | −238 | 28 | 168 |
| Diluted EPS (US$) | −3.04 | −4.48 | −3.22 | 1.23 | 1.62 | −3.81 | −3.76 | −2.53 | 0.25 | 1.43 |
| Diluted shares (millions) | 42 | 53 | 65 | 73 | 84 | 75 | 78 | 94 | 115 | 117 |
| Cash flow | ||||||||||
| Cash from operations | −252 | −200 | −159 | 28 | 154 | −37 | −241 | −175 | −20 | −138 |
| Capital expenditure | 6 | 5 | 1 | 2 | 7 | 1 | 2 | 0 | — | — |
| Free cash flow | −259 | −205 | −160 | 27 | 147 | −39 | −243 | −175 | — | — |
| Dividends paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Share buybacks | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Acquisitions | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Stock-based compensation | 27 | 33 | 35 | 34 | 38 | 51 | 51 | 43 | 28 | 17 |
| Balance sheet at fiscal year end | ||||||||||
| Cash and short-term investments | 125 | 127 | 72 | 178 | 541 | 417 | 192 | 118 | — | 172 |
| Debt incl. finance leases | 75 | 76 | 77 | 78 | 81 | 83 | — | — | — | — |
| Total assets | 178 | 163 | 100 | 409 | 842 | 679 | 481 | 630 | 448 | 258 |
| Total liabilities | 159 | 132 | 138 | 304 | 561 | 582 | 618 | 823 | 580 | 197 |
| Shareholders' equity | 20 | 30 | −39 | 105 | 281 | 98 | −137 | −193 | −132 | 61 |
| Margins and ratios | ||||||||||
| Gross margin | — | — | — | 95.2% | 92.1% | 82.4% | 66.8% | 38.2% | 66.9% | 67.2% |
| Operating margin | −61.0% | −14,918.8% | — | 30.3% | 32.9% | −80.8% | −121.7% | −79.0% | −756.6% | −429.5% |
| Net margin | −67.0% | −15,306.6% | — | 25.2% | 27.8% | −87.9% | −138.2% | −92.5% | 108.0% | 398.4% |
| Free cash flow margin | −136.3% | −13,165.8% | — | 7.5% | 30.9% | −11.9% | −115.2% | −68.1% | — | — |
| Rule of 40 (growth + FCF margin) | 396.6% | −13,264.9% | — | — | 64.5% | −43.2% | −150.6% | −46.2% | — | — |
| Return on capital | — | — | — | — | — | — | — | — | — | — |
| Return on equity | — | −932.9% | — | 269.7% | 68.5% | −151.6% | — | — | — | — |
| Return on assets | −65.2% | −139.7% | −159.8% | 35.3% | 21.1% | −37.8% | −50.3% | −42.9% | 5.3% | 47.5% |
| Net debt to EBITDA | — | — | — | −0.9x | −2.9x | — | — | — | — | — |